^
    Back
    Association details:
    Biomarker:MYD88 mutation
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    BMJ Case Rep
    Title:

    IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid

    Published date:
    02/23/2021
    Excerpt:
    ...76-year-old man...Bone marrow biopsy showed lymphoplasmocytoid lymphoma (Waldenstrom's macroglobulinaemia, WM), consequently positive for MYD88 mutation. His sensory symptoms have improved following rituximab treatment and his WM is under control.
    DOI:
    10.1136/bcr-2020-240242